Uveitis Treatment Market

Market Overview

The global uveitis treatment market size was worth USD 478 million in 2018 and is expected to reach USD 687 million by 2026, growing at a 4.5% CAGR during 2019-2026.

Anterior uveitis is an infection of the retina's middle layer, which includes the iris (colored part of the eye) and ciliary muscle (adjacent tissue). Untreated anterior uveitis results in vision loss and significant eye damage, which may progress to retinal edeoma, cataract, or glaucoma. To treat anterior uveitis, anti-inflammatory eye drops should be utilized. Treatment is often more effective for it. Further, the disease may tend to persist. Uveitis is an under-researched symptom that may be treated with a range of medications, including biologics and corticosteroids.

Corticosteroids have been demonstrated to be beneficial in the treatment of anterior uveitis, and physicians are increasingly considering biological therapy. The introduction of biologics for the diagnosis of uveitis, such as Humira (Adalimumab), is boosting the Asia Pacific anterior uveitis market. Numerous companies are involved in the uveitis industry, and developing new medications and expanding the clinical usage of established treatments to include and effectively treat uveitis represents a significant growth opportunity.

Market Dynamics

The Market's Expansion is Aided By an Increase in the Number of Clinics:

The increasing prevalence of anterior uveitis and its consequences globally, the high incidence of autoimmune illnesses globally, the surge in the development of biological therapies for the treatment of uveitis, the rising demand for innovative healthcare goods, and the increasing number of government initiatives to decrease e-waste all contribute to the market's growth. Further, the ophthalmological sector has experienced a rapid increase in research and development operations for novel medication discovery, which has aided in the production of optimum medicines. As funding for research and development increases, further clinical studies for treating ocular inflammation are being done worldwide. Numerous new stage III clinical studies for refractory post- or moderate-grade uveitis are now underway. This creates several opportunities for the anterior uveitis treatment sector to grow.

Further, the market's prominent players have been recognized to put a higher premium on technological advancements and the expedited introduction of new and developing goods. As an outcome, ophthalmologists are focusing their efforts on developing novel pharmaceutical formulations that will help reduce anterior uveitis and allow them to deliver superior ocular therapy and patient care. This also results in improved performance and safety profiles throughout the clinical trial stage of development, leading to a significant reduction in disease progression.

Other factors contributing to the market's growth include the expanding elderly population, the expedited clearance of pipeline medications, people's increasing disposable incomes paired with high healthcare expenditure, and the growing number of medical studies for ocular inflammation therapy. Moreover, the expanding number of clinics, medical facilities, and internet therapies all contribute to the market's growth.

Segmental Analysis

Insights on Treatment Types

Numerous therapy options are available, including corticosteroids, immunosuppressants, cycloplegic medicines, and anti-TNF drugs. In 2018, corticosteroids dominated the market for anterior uveitis treatment, since they are the first-line therapy for anterior uveitis. They are used as eye drops and in systemic treatment. Additionally, corticosteroids are employed in sustained-release therapy, i.e., ocular implants. Prednisolone acetate, betamethasone, dexamethasone sodium phosphate, fluorometholone, loteprednol, and rimexolone are all popular topical corticosteroid medications.

Anti-TNF drugs are employed as anti-inflammatory medications, while cycloplegic agents are used for both disease diagnostics and therapy. On the other side, immunosuppressive medicines work by altering the immune system's normal function in order to alleviate inflammation. These medications are mostly utilized in situations with corticosteroid resistance or chronic uveitis.

The Uveitis Market is Predicted to Grow Rapidly

The market is segmented by disease type into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis sector is expected to expand significantly throughout the projected period, leading to the growing prevalence of uveitis. The most common type of uveitis is anterior uveitis, which is defined by inflammation of the main layer of the eye, which includes the iris and the neighboring tissue known as the ciliary body.

Anterior Uveitis is One of the Most Often Reported Types

The new product uses and treatment approaches are constantly being developed; for example, the approval of Humira for the treatment of uveitis was a key development. As a result, factors such as the growing aging population, increased illness incidence, and new product advancements are predicted to be major drivers. Eye redness, blurred vision, a narrow pupil, and sensitivity to light are all potential markers of anterior uveitis, which, if remaining unattended, may cause lifelong blindness.

Increased prevalence of ocular infections, together with growing knowledge of available therapies, is expected to support market expansion during the projected period. Other market drivers include high healthcare expenditures, rising disposable income, and favorable government policies. Anterior uveitis is one of the most often reported kinds of ocular inflammation to primary eye care specialists.

Intraocular pressure could be changed in patients with anterior uveitis (IOP). As a consequence, blood may accumulate in the anterior chamber, impairing vision. Corticosteroid therapy may result in an increase in IOP, which is a side effect of the medicine. Glaucoma, cataract, cystoid macular edoema, and band keratopathy are just a few of the serious problems linked with this form of eye illness.

Impact of covid-19

The Asia Pacific has a high frequency of anterior uveitis. For example, according to research published in April 2019 in the journal Clinical and Experimental Ophthalmology titled 'Epidemiology of uveitis in metropolitan Australia,' the most frequent uveitis cases were anterior (75%), intermediate (6%), posterior (15%), and panuveitis (15%). (4 percent ).

Numerous therapeutic studies have been discontinued because of the discovery of Covid-19. For example, Galapagos stated in March 2020 that it is suspending enrolment in many clinical studies, including its Phase II and Phase III filgotinib trials in Crohn's disease, psoriatic arthritis, and uveitis.

Regional Analysis

North America Will Prevail in the Uveitis Treatment Market:

One of the reasons driving the market's development is the increasing demand for pharmaceuticals such as corticosteroids and anti-inflammatory treatments to treat uveitis in emerging nations. For example, according to a 2013 National Center for Biotechnology Information (NCBI) article, uveitis is the main cause of blindness in underdeveloped nations, including India. Around 25% of blindness is linked to uveitis, and associated consequences such as glaucoma, cataract, and optic nerve damage all contribute to blindness.

Additionally, the NCBI reports that the incidence of blindness caused by uveitis varies between 3% and 10% in affluent nations. For example, in the United States, figures from 2013 indicated that 10% of blindness caused by uveitis occurred in California. Additionally, the numbers indicated that the incidence is expected to be between 3% and 7% throughout Europe. In industrialized nations, uveitis is thought to be caused by an organ-specific immune-inflammatory process. Whereas infections are blamed for blindness caused by uveitis in poorer areas. As a result of increased knowledge about correct etiologic diagnosis and treatment in emerging countries like India, the uveitis treatment market is expected to rise at a profitable rate over the projected period.

North America presently dominates the region's uveitis treatment market. This is due to a number of causes, including the expanding elderly population, an increase in eye-related disorders—particularly uveitis—and increased investment in uveitis-related research and development, as well as the availability of treatments.

Over the predicted period, Asia Pacific is anticipated to have profitable growth. India and China are expected to have considerable expansion in the uveitis treatment industry. This is due to increased disposable income and an increase in the number of people diagnosed with uveitis.